Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC)
    Meeting Abstract

    Hamilton, A.; Kelley, R. K.; Li, D.; Bermejo, I. M.; Abou-Alfa, G. K.; Alese, O. B.; Al-Rajabi, R. M. T.; Babiker, H. M.; Borad, M.; Dayyani, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Critical roles of type I interferon receptor signaling in myeloid and T cells for virus-induced antitumor responses
    Meeting Abstract

    Baseer Tariq, S.; Wang, Y.; Wang, W.; Salla, B.; Wang, Y.; Liu, S.; Yang, N.; Li, M.; Deng, L.
    Journal of Investigative Dermatology (2024)

    Fulltext@MSK | Save
  • Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer
    Meeting Abstract

    Boiarsky, D.; Hong, L.; Ricciuti, B.; Cooper, A. J.; Saad, M. B.; Elkrief, A.; Di Federico, A.; Aminu, M.; Rinsurongkawong, W.; Lewis, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39
    Meeting Abstract

    Bedke, J.; Van Der Heijden, M. S.; Powles, T.; Valderrama, B. P.; Kikuchi, E.; Iyer, G.; Vulsteke, C.; Swami, U.; Castellano, D.; Sarwar, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • irst-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses
    Meeting Abstract

    Juric, D.; Kalinsky, K.; Turner, N. C.; Jhaveri, K. L.; Schmid, P.; Loi, S.; Saura, C.; Im, S. A.; Sunpaweravong, P.; Li, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3
    Meeting Abstract

    Hussein, M. A.; Khan, G.; Chandana, S. R.; Cid, R. A. P.; Kiss, I.; Gallego, J.; Macarulla, T.; De la Fouchardiere, C.; Goetze, T.; Dean, A. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study
    Meeting Abstract

    Pernas, S.; Im, S. A.; Hattori, M.; Xu, B.; Wang, S.; Lu, Y. S.; Borges, G.; Tsurutani, J.; Jhaveri, K. L.; Zhang, Q. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39
    Meeting Abstract

    Van Der Heijden, M. S.; Gupta, S.; Bedke, J.; Valderrama, B. P.; Kikuchi, E.; Iyer, G.; Loriot, Y.; Dawson, N. A.; Hoffman-Censits, J. H.; Mar, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis
    Meeting Abstract

    Rampal, R.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Seven-year overall survival analysis from ECHELON-1 study of A+ AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma
    Meeting Abstract

    Ansell, S. M.; Straus, D. J.; Connors, J. M.; Jurczak, W.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R. H.; Hutchings, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save